A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Inclusion Criteria:

• Body mass index within the range of >= 25 and <=45 kilograms per square meter (kg/m^2)

• MASH with fibrosis score of F3 or F4 confirmed by transient elastography measurement >=12.0 kPa and <=25.0 kPa

• Agreement to adhere to the contraception requirements

Exclusion Criteria:

• Weight gain or loss >5% in the 3 months prior to baseline or >10% in the 6 monthsprior to baseline

• Bariatric surgery within 1 year prior to baseline

• Current signs or prior history of decompensated liver disease

• Complications or clinical evidence of portal hypertension

• Lack of peripheral venous access

• Other causes of liver disease based on medical history and/or centralized review ofliver histology

• History of liver transplantation

• Current or prior history of hepatocellular carcinoma (HCC)

• Uncontrolled hypertension

• Concomitant Type 1 diabetes, or Type 2 diabetes with HbA1c >10%

• History of malignancy within 5 years prior to screening, with the exception ofmalignancies with a negligible risk of metastasis or death

• Current, significant alcohol consumption or a history of significant alcoholconsumption for a period of more than 3 consecutive months any time within 1 yearprior to screening

• Initiation of a medication of an antidiabetic, weight loss, lipid-modifying oranti-depressant drug class

• Active tuberculosis requiring treatment within the 12 months prior to baseline

• History of organ transplant